GLUL and neoplasm: The reduction of glutamate-ammonia ligase (GLUL) expression, the low levels of glutamine metabolism genes ASNS, ASS1, of the transporter SLC1A5 and the reduced level of pantothenic acid may reflect a more general adaptation based on metabolic rewiring that characterizes drug resistance in tumour cells [64].